GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (NAS:CERS) » Definitions » PS Ratio

Cerus (CERS) PS Ratio

: 1.95 (As of Today)
View and export this data going back to 1997. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cerus's share price is $1.69. Cerus's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.87. Hence, Cerus's PS Ratio for today is 1.95.

The historical rank and industry rank for Cerus's PS Ratio or its related term are showing as below:

CERS' s PS Ratio Range Over the Past 10 Years
Min: 1.48   Med: 10.05   Max: 21.24
Current: 1.94

During the past 13 years, Cerus's highest PS Ratio was 21.24. The lowest was 1.48. And the median was 10.05.

CERS's PS Ratio is ranked better than
65.88% of 809 companies
in the Medical Devices & Instruments industry
Industry Median: 3.15 vs CERS: 1.94

Cerus's Revenue per Sharefor the three months ended in Dec. 2023 was $0.26. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.87.

Warning Sign:

Cerus Corp revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Cerus was -5.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 15.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 15.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 7.60% per year.

During the past 13 years, Cerus's highest 3-Year average Revenue per Share Growth Rate was 52.40% per year. The lowest was -44.50% per year. And the median was 9.15% per year.

Back to Basics: PS Ratio


Cerus PS Ratio Historical Data

The historical data trend for Cerus's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.90 12.34 8.91 3.98 2.49

Cerus Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.98 3.39 2.86 1.89 2.49

Competitive Comparison

For the Medical Devices subindustry, Cerus's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cerus PS Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Cerus's PS Ratio distribution charts can be found below:

* The bar in red indicates where Cerus's PS Ratio falls into.



Cerus PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Cerus's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.69/0.867
=1.95

Cerus's Share Price of today is $1.69.
Cerus's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.87.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Cerus  (NAS:CERS) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Cerus PS Ratio Related Terms

Thank you for viewing the detailed overview of Cerus's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cerus (CERS) Business Description

Traded in Other Exchanges
Address
1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Executives
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Ann Lucena director C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD CA 94520
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Gail Schulze director 3451 WELLS ROAD, MALVERN PA 19355
Laurence M Corash director C/O CERUS CORP, 2411 STENWELL DRIVE, CONCORD CA 94520
William Mariner Greenman officer: President, Cerus Europe C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Chrystal Menard officer: Chief Legal Officer C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Kevin Dennis Green officer: Chief Accounting Officer C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Richard J Benjamin officer: Chief Medical Officer 15 WHITE PINE ROAD, NEWTON MA 02464
Vivek K Jayaraman officer: Chief Commercial Officer 3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Hua Shan director C/O CERUS CORPORATION, 1220 CONCORD AVE., STE. 600, CONCORD CA 94520
Carol Moore officer: SR. V.P. Regulatory, Clinical C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Timothy B Anderson director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Timothy L. Moore director C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Frank Witney director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451